3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Breast
1
Conditions
Breast Neoplasms
106
Neoplasms
14
Neoplasm Metastasis
14
Carcinoma, Non-Small-Cell Lung
4
Advanced Breast Cancer
4
Hereditary Sensory and Autonomic Neuropathies
3
Recurrence
2
Prostatic Neoplasms
2
Ovarian Neoplasms
2
Multiple Endocrine Neoplasia Type 1
2
Endometrial Neoplasms
2
Breast Neoplasms, Male
2
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urologic Neoplasms
1
Triple Negative Breast Neoplasms
1
Stomach Neoplasms
1
Solid Malignancies
1
Recurrent Uterine Corpus Carcinoma
1
Neoplasms by Site
1
Lymphoma, Non-Hodgkin
1
Lymphoma
1
Locally Advanced (Inoperable) or Metastatic Breast Cancer
1
Lethal Congenital Contracture Syndrome 2
1
Hyperglycemia
1
Hormone Receptor Positive HER-2 Negative Breast Cancer
1
Hormone Receptor Positive Breast Cancer
1
HER2-positive Breast Cancer
1
Female Breast Carcinoma
1
Exanthema
1
Interventions
Radiotherapy
3
Carboplatin
3
Trastuzumab
2
Magnetic Resonance Spectroscopy
2
Cyclophosphamide
2
proto-oncogene protein c-fes-fps
1
palbociclib
1
gallium 68 PSMA-11
1
fluciclovine F-18
1
Vorinostat
1
Thiotepa
1
Taxes
1
Tamoxifen
1
Sugars
1
Radiation
1
Paclitaxel
1
Naltrexone
1
Melphalan
1
Letrozole
1
Fulvestrant
1
Fluorine-18
1
Drugs, Generic
1
Doxorubicin
1
Docetaxel
1
Crizotinib
1
Counseling
1
Chemotherapy, Adjuvant
1
Albumin-Bound Paclitaxel
1
68Ga-DKFZ-PSMA-11
1
130-nm albumin-bound paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Carcinoma, Lobular
×
Fulvestrant
×
Clear all
NCT03620643
2025-10-30
ROLo
Royal Marsden NHS Foundation Trust
Phase 2
Completed
33 enrolled
13 charts